Company adds Phase II-ready VEGF receptor inhibitor to growing product portfolio.
Aveo Pharmaceuticals obtained an exclusive license to develop and commercialize Kirin Brewery’s once-a-day, oral VEGF receptor inhibitor, KRN951, in all territories outside of Asia.
Aveo initially plans to develop KRN951 for the treatment of renal cell carcinoma. The company expects to commence Phase II studies by mid-2007. In an ongoing 30-patient Phase I trial in advanced solid tumors, all seven patients with refractory renal cell carcinoma achieved either a partial response or stable disease as defined by the trial protocol, with one patient exhibiting a response lasting more than two and half years.
Aveo will also develop this VEGF receptor inhibitor as a combination treatment in multiple solid tumor types. The company will apply its Human Response Prediction™ Platform to identify optimal chemotherapy combinations, as well as additional patient populations likely to respond to KRN951 monotherapy and combination therapy.
